Autor segons l'article: Gonzalez-Clemente, Jose-Miguel; Cano, Albert; Albert, Lara; Gimenez-Palop, Olga; Romero, Ana; Berlanga, Eugenio; Vendrell, Joan; Llaurado, Gemma;
Departament: Medicina i Cirurgia
Autor/s de la URV: Vendrell Ortega, Juan José
Paraules clau: Very low density lipoprotein Untranslated rna Type 1 diabetes Triacylglycerol Treatment outcome Tonometry Target organ Risk-factors Review Renin angiotensin aldosterone system Recommendations Pulse wave velocity Pulse wave Prospective study Prediction Peripheral neuropathy Pathophysiology Parathyroid hormone Oscillometry Nuclear magnetic resonance imaging Non invasive measurement Nitric oxide Microvasculature Microvascular complications Microrna Mechanisms Measurement Low density lipoprotein Liraglutide Lipoprotein particles Lipoprotein Insulin resistance Insulin dependent diabetes mellitus Inflammation Hypertension Hyperglycemia Hypercholesterolemia Hydroxymethylglutaryl coenzyme a reductase inhibitor Human High density lipoprotein Ezetimibe Expert consensus document Evolocumab Endothelial dysfunction Empagliflozin Elastin Elasticity Echocardiography Drug effect Double diabetes Diuretic agent Diabetic retinopathy Diabetic neuropathy Diabetic nephropathy Diabetic microangiopathy Diabetic complication Diabetes mellitus Cross-sectional study Collagen Clinical practice Cholesterol Cardiovascular-disease Cardiovascular risk Cardiovascular disease Cardiac autonomic neuropathy Calcium channel blocking agent Blood pressure Biological marker Beta adrenergic receptor blocking agent Atherosclerotic plaque Atherosclerosis Association Artery calcification Arterial stiffness Apolipoprotein a5 Aortic stiffness Aorta Antihypertensive therapy Alirocumab Albuminuria Aging Adult Adiponectin
Resum: Arterial stiffness (AS) integrates the cumulative burden of known and unknown cardiovascular risk factors on the elastic wall of large arteries along the lifespan of an individual. As a marker of vascular aging, AS is an independent predictor of cardiovascular events and improves cardiovascular risk prediction when added to the Framingham Risk Score. In addition, AS may affect the microvasculature and promote the development of microvascular complications. Its impact on both the macro- and microvasculature has led to the concept that the arterial wall itself should be considered as a target organ. Here, we review the biological and clinical consequences of AS on the macro- and microvasculature and the measurement of AS in routine clinical practice. We also discuss the pathophysiological mechanisms underpinning AS development using diabetes and, in particular, type 1 diabetes, as a disease model with a high risk of cardiovascular events and microvascular complications that are accelerated by AS.
Àrees temàtiques: Medicine, general & internal Medicine (miscellaneous) Medicine (all)
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: juanjose.vendrell@urv.cat
Identificador de l'autor: 0000-0002-6994-6115
Data d'alta del registre: 2024-07-27
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Journal Of Clinical Medicine. 10 (16):
Referència de l'ítem segons les normes APA: Gonzalez-Clemente, Jose-Miguel; Cano, Albert; Albert, Lara; Gimenez-Palop, Olga; Romero, Ana; Berlanga, Eugenio; Vendrell, Joan; Llaurado, Gemma; (2021). Arterial Stiffness in Type 1 Diabetes: The Case for the Arterial Wall Itself as a Target Organ. Journal Of Clinical Medicine, 10(16), -. DOI: 10.3390/jcm10163616
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV